Mohamed A. Gaballa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed A. Gaballa has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Liudmila Zakharova
Center for Cardiovascular Research, Banner Sun Health Research Institute, Sun City, Arizona, USA
5 shared publicationsHikmet Nural-Guvener
Center for Cardiovascular Research, Banner Sun Health Research Institute, Sun City, Arizona, USA
3 shared publicationsLorraine Feehery
Center for Cardiovascular Research, Banner Sun Health Research Institute, Sun City, Arizona, USA
2 shared publicationsSnjezana Popovic
Center for Cardiovascular Research, Banner Sun Health Research Institute, Sun City, Arizona
2 shared publicationsDiego Mastroeni
Cardiovascular Research Laboratory, Center for Cardiovascular Research , Banner Sun Health Research Institute , 10515 W. Santa Fe Drive, Sun City, AZ 85351 , USA
1 shared publication- Diego Mastroeni
L. J Roberts Center for Alzheimer’s Research at Banner Sun Health Research Institute, Sun City, AZ, USA
1 shared publication
Latest Publications
- Open Access
- 3 August 2015
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 4 (9) , 1086-1096
Transplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model
Cardiac c-Kit+ cells have a modest cardiogenic potential that could limit their efficacy in heart disease treatment. The present study was designed to augment the cardiogenic potential of cardiac c-Kit+ cells through class I histone deacetylase (HDAC) inhibition and evaluate their therapeutic potency in the chronic heart failure (CHF) animal model. Myocardial infarction (MI) was created by coronary artery occlusion in rats. c-Kit+ cells were treated with mocetinostat (MOCE), a specific class I HDAC inhibitor. At 3 weeks after MI, CHF animals were retrogradely infused with untreated (control) or MOCE-treated c-Kit+ cells (MOCE/c-Kit+ cells) and evaluated at 3 weeks after cell infusion. We found that class I HDAC inhibition in c-Kit+ cells elevated the level of acetylated histone H3 (AcH3) and increased AcH3 levels in the promoter regions of pluripotent and cardiac-specific genes. Epigenetic changes were accompanied by increased expression of cardiac-specific markers. Transplantation of CHF rats with either control or MOCE/c-Kit+ cells resulted in an improvement in cardiac function, retardation of CHF remodeling made evident by increased vascularization and scar size, and cardiomyocyte hypertrophy reduction. Compared with CHF infused with control cells, infusion of MOCE/c-Kit+ cells resulted in a further reduction in left ventricle end-diastolic pressure and total collagen and an increase in interleukin-6 expression. The low engraftment of infused cells suggests that paracrine effects might account for the beneficial effects of c-Kit+ cells in CHF. In conclusion, selective inhibition of class I HDACs induced expression of cardiac markers in c-Kit+ cells and partially augmented the efficacy of these cells for CHF repair. Significance: The study has shown that selective class 1 histone deacetylase inhibition is sufficient to redirect c-Kit+ cells toward a cardiac fate. Epigenetically modified c-Kit+ cells improved contractile function and retarded remodeling of the congestive heart failure heart. This study provides new insights into the efficacy of cardiac c-Kit+ cells in the ischemic heart failure model.
- 3 August 2015
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 4 (9) , 1086-1096
Open AccessTransplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model
Cardiac c-Kit+ cells have a modest cardiogenic potential that could limit their efficacy in heart disease treatment. The present study was designed to augment the cardiogenic potential of cardiac c-Kit+ cells through class I histone deacetylase (HDAC) inhibition and evaluate their therapeutic potency in the chronic heart failure (CHF) animal model. Myocardial infarction (MI) was created by coronary artery occlusion in rats. c-Kit+ cells were treated with mocetinostat (MOCE), a specific class I HDAC inhibitor. At 3 weeks after MI, CHF animals were retrogradely infused with untreated (control) or MOCE-treated c-Kit+ cells (MOCE/c-Kit+ cells) and evaluated at 3 weeks after cell infusion. We found that class I HDAC inhibition in c-Kit+ cells elevated the level of acetylated histone H3 (AcH3) and increased AcH3 levels in the promoter regions of pluripotent and cardiac-specific genes. Epigenetic changes were accompanied by increased expression of cardiac-specific markers. Transplantation of CHF rats with either control or MOCE/c-Kit+ cells resulted in an improvement in cardiac function, retardation of CHF remodeling made evident by increased vascularization and scar size, and cardiomyocyte hypertrophy reduction. Compared with CHF infused with control cells, infusion of MOCE/c-Kit+ cells resulted in a further reduction in left ventricle end-diastolic pressure and total collagen and an increase in interleukin-6 expression. The low engraftment of infused cells suggests that paracrine effects might account for the beneficial effects of c-Kit+ cells in CHF. In conclusion, selective inhibition of class I HDACs induced expression of cardiac markers in c-Kit+ cells and partially augmented the efficacy of these cells for CHF repair. Significance: The study has shown that selective class 1 histone deacetylase inhibition is sufficient to redirect c-Kit+ cells toward a cardiac fate. Epigenetically modified c-Kit+ cells improved contractile function and retarded remodeling of the congestive heart failure heart. This study provides new insights into the efficacy of cardiac c-Kit+ cells in the ischemic heart failure model.
- Open Access
- 2 July 2014
- Published by Springer Nature in Fibrogenesis & Tissue Repair
- Vol. 7 (1) , 10
HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation
Interstitial fibrosis and fibrotic scar formation contribute to cardiac remodeling and loss of cardiac function in myocardial infarction (MI) and heart failure. Recent studies showed that histone deacetylase (HDAC) inhibitors retard fibrosis formation in acute MI settings. However, it is unknown whether HDAC inhibition can reverse cardiac fibrosis in ischemic heart failure. In addition, specific HDAC isoforms involved in cardiac fibrosis and myofibroblast activation are not well defined. Thus, the purpose of this study is to determine the effects of selective class I HDAC inhibition on cardiac fibroblasts activation and cardiac fibrosis in a congestive heart failure (CHF) model secondary to MI.
- 2 July 2014
- Published by Springer Nature in Fibrogenesis & Tissue Repair
- Vol. 7 (1) , 10
Open AccessHDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation
Interstitial fibrosis and fibrotic scar formation contribute to cardiac remodeling and loss of cardiac function in myocardial infarction (MI) and heart failure. Recent studies showed that histone deacetylase (HDAC) inhibitors retard fibrosis formation in acute MI settings. However, it is unknown whether HDAC inhibition can reverse cardiac fibrosis in ischemic heart failure. In addition, specific HDAC isoforms involved in cardiac fibrosis and myofibroblast activation are not well defined. Thus, the purpose of this study is to determine the effects of selective class I HDAC inhibition on cardiac fibroblasts activation and cardiac fibrosis in a congestive heart failure (CHF) model secondary to MI.
- 1 June 2014
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 33 (6) , 644-653
Retrograde coronary vein infusion of cardiac explant–derived c-Kit+ cells improves function in ischemic heart failure
- 1 June 2014
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 33 (6) , 644-653
Retrograde coronary vein infusion of cardiac explant–derived c-Kit+ cells improves function in ischemic heart failure
- Open Access
- 26 September 2013
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 2 (5) , e000317
Chronic Heart Failure Is Associated With Transforming Growth Factor Beta‐Dependent Yield and Functional Decline in Atrial Explant‐Derived c‐Kit+ Cells
Background: Cardiac c‐Kit+ cells isolated from cardiac explant‐derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized. For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure ( CHF ), and it is unclear how this disease affects the explant‐derived progenitor cells. Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c‐Kit+ progenitors and elucidate mechanisms of their regulation. Methods and Results: Myocardial infarction was created by left anterior descending coronary artery occlusion. Sham‐operated animals were used as a control group. CHF ‐developed infarcted animals were selected on the basis of left ventricle end‐diastolic pressure ≥20 mm Hg and scar size ≥30%. Here, we found that CHF atrial explants produced less c‐Kit+ cells than sham explants. CHF ‐derived c‐Kit+ cells exhibited upregulated transforming growth factor–β ( TGF ‐β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams. We show that intervention with TGF ‐β signaling by inhibiting TGF ‐β receptor type I or Smad 2/3 using small‐molecule inhibitors improved c‐Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c‐Kit+ cell differentiation toward cardiomyocyte‐like cells in vitro. Conclusions: Taken together, our findings suggest that TGF ‐β inhibition positively modulates c‐Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.
- 26 September 2013
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 2 (5) , e000317
Open AccessChronic Heart Failure Is Associated With Transforming Growth Factor Beta‐Dependent Yield and Functional Decline in Atrial Explant‐Derived c‐Kit+ Cells
Background: Cardiac c‐Kit+ cells isolated from cardiac explant‐derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized. For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure ( CHF ), and it is unclear how this disease affects the explant‐derived progenitor cells. Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c‐Kit+ progenitors and elucidate mechanisms of their regulation. Methods and Results: Myocardial infarction was created by left anterior descending coronary artery occlusion. Sham‐operated animals were used as a control group. CHF ‐developed infarcted animals were selected on the basis of left ventricle end‐diastolic pressure ≥20 mm Hg and scar size ≥30%. Here, we found that CHF atrial explants produced less c‐Kit+ cells than sham explants. CHF ‐derived c‐Kit+ cells exhibited upregulated transforming growth factor–β ( TGF ‐β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams. We show that intervention with TGF ‐β signaling by inhibiting TGF ‐β receptor type I or Smad 2/3 using small‐molecule inhibitors improved c‐Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c‐Kit+ cell differentiation toward cardiomyocyte‐like cells in vitro. Conclusions: Taken together, our findings suggest that TGF ‐β inhibition positively modulates c‐Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.
- Open Access
- 25 May 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (5) , e37800
Cardiac Explant-Derived Cells Are Regulated by Notch-Modulated Mesenchymal Transition
Progenitor cell therapy is emerging as a novel treatment for heart failure. However the molecular mechanisms regulating the generation of cardiac progenitor cells is not fully understood. We hypothesized that cardiac progenitor cells are generated from cardiac explant via a process similar to epithelial to mesenchymal transition (EMT). Explant-derived cells were generated from partially digested atrial tissue. After 21 days in culture, c-Kit+ cells were isolated from cell outgrowth. The majority of explant-originated c-Kit+ cells expressed the epicardial marker Wt1. Cardiac cell outgrowth exhibits a temporal up-regulation of EMT-markers. Notch stimulation augmented, while Notch inhibition suppressed, mesenchymal transition in both c-Kit+ and c-Kit- cells. In c-Kit+ cells, Notch stimulation reduced, while Notch inhibition up-regulated pluripotency marker expressions such as Nanog and Sox2. Notch induction was associated with degradation of β-catenin in c-Kit- cells. In contrast, Notch inhibition resulted in β-catenin accumulation, acquisition of epitheloid morphology, and up-regulation of Wnt target genes in c-Kit- cells. Our study suggests that Notch-mediated reversible EMT process is a mechanism that regulates explant-derived c-Kit+ and c-Kit- cells.
- 25 May 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (5) , e37800
Open AccessCardiac Explant-Derived Cells Are Regulated by Notch-Modulated Mesenchymal Transition
Progenitor cell therapy is emerging as a novel treatment for heart failure. However the molecular mechanisms regulating the generation of cardiac progenitor cells is not fully understood. We hypothesized that cardiac progenitor cells are generated from cardiac explant via a process similar to epithelial to mesenchymal transition (EMT). Explant-derived cells were generated from partially digested atrial tissue. After 21 days in culture, c-Kit+ cells were isolated from cell outgrowth. The majority of explant-originated c-Kit+ cells expressed the epicardial marker Wt1. Cardiac cell outgrowth exhibits a temporal up-regulation of EMT-markers. Notch stimulation augmented, while Notch inhibition suppressed, mesenchymal transition in both c-Kit+ and c-Kit- cells. In c-Kit+ cells, Notch stimulation reduced, while Notch inhibition up-regulated pluripotency marker expressions such as Nanog and Sox2. Notch induction was associated with degradation of β-catenin in c-Kit- cells. In contrast, Notch inhibition resulted in β-catenin accumulation, acquisition of epitheloid morphology, and up-regulation of Wnt target genes in c-Kit- cells. Our study suggests that Notch-mediated reversible EMT process is a mechanism that regulates explant-derived c-Kit+ and c-Kit- cells.
- Open Access
- 29 January 2010
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 87 (1) , 40-49
Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function
Cell-based therapy for myocardial infarction (MI) holds great promise; however, the ideal cell type and delivery system have not been established. Obstacles in the field are the massive cell death after direct injection and the small percentage of surviving cells differentiating into cardiomyocytes. To overcome these challenges we designed a novel study to deliver cardiac progenitor cells as a cell sheet. Cell sheets composed of rat or human cardiac progenitor cells (cardiospheres), and cardiac stromal cells were transplanted onto the infarcted myocardium after coronary artery ligation in rats. Three weeks later, transplanted cells survived, proliferated, and differentiated into cardiomyocytes (14.6 ± 4.7%). Cell sheet transplantation suppressed cardiac wall thinning and increased capillary density (194 ± 20 vs. 97 ± 24 per mm2, P < 0.05) compared with the untreated MI. Cell migration from the sheet was observed along the necrotic trails within the infarcted area. The migrated cells were located in the vicinity of stromal-derived factor (SDF-1) released from the injured myocardium, and about 20% of these cells expressed CXCR4, suggesting that the SDF-1/CXCR4 axis plays, at least, a role in cell migration. Transplantation of cell sheets resulted in a preservation of cardiac contractile function after MI, as was shown by a greater ejection fraction and lower left ventricular end diastolic pressure compared with untreated MI. The scaffold-free cardiosphere-derived cell sheet approach seeks to efficiently deliver cells and increase cell survival. These transplanted cells effectively rescue myocardium function after infarction by promoting not only neovascularization but also inducing a significant level of cardiomyogenesis.
- 29 January 2010
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 87 (1) , 40-49
Open AccessTransplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function
Cell-based therapy for myocardial infarction (MI) holds great promise; however, the ideal cell type and delivery system have not been established. Obstacles in the field are the massive cell death after direct injection and the small percentage of surviving cells differentiating into cardiomyocytes. To overcome these challenges we designed a novel study to deliver cardiac progenitor cells as a cell sheet. Cell sheets composed of rat or human cardiac progenitor cells (cardiospheres), and cardiac stromal cells were transplanted onto the infarcted myocardium after coronary artery ligation in rats. Three weeks later, transplanted cells survived, proliferated, and differentiated into cardiomyocytes (14.6 ± 4.7%). Cell sheet transplantation suppressed cardiac wall thinning and increased capillary density (194 ± 20 vs. 97 ± 24 per mm2, P < 0.05) compared with the untreated MI. Cell migration from the sheet was observed along the necrotic trails within the infarcted area. The migrated cells were located in the vicinity of stromal-derived factor (SDF-1) released from the injured myocardium, and about 20% of these cells expressed CXCR4, suggesting that the SDF-1/CXCR4 axis plays, at least, a role in cell migration. Transplantation of cell sheets resulted in a preservation of cardiac contractile function after MI, as was shown by a greater ejection fraction and lower left ventricular end diastolic pressure compared with untreated MI. The scaffold-free cardiosphere-derived cell sheet approach seeks to efficiently deliver cells and increase cell survival. These transplanted cells effectively rescue myocardium function after infarction by promoting not only neovascularization but also inducing a significant level of cardiomyogenesis.